<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org).">
  <meta name="generator" content="bookdown 0.0.79 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="github-repo" content="shanmdphd/PAPER" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-07-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="first-session.html">
<link rel="next" href="translation-and-convergence-for-future-medicine.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>2</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="2.1" data-path="opening-remark.html"><a href="opening-remark.html"><i class="fa fa-check"></i><b>2.1</b> Opening Remark</a></li>
<li class="chapter" data-level="2.2" data-path="first-session.html"><a href="first-session.html"><i class="fa fa-check"></i><b>2.2</b> First Session</a><ul>
<li class="chapter" data-level="2.2.1" data-path="first-session.html"><a href="first-session.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>2.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="2.2.2" data-path="first-session.html"><a href="first-session.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>2.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="2.2.3" data-path="first-session.html"><a href="first-session.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>2.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="second-session.html"><a href="second-session.html"><i class="fa fa-check"></i><b>2.3</b> Second Session</a><ul>
<li class="chapter" data-level="2.3.1" data-path="second-session.html"><a href="second-session.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>2.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="2.3.2" data-path="second-session.html"><a href="second-session.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>2.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="2.3.3" data-path="second-session.html"><a href="second-session.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>2.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="2.3.4" data-path="second-session.html"><a href="second-session.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>2.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>3</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="3.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html"><i class="fa fa-check"></i><b>3.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="3.1.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-1--------"><i class="fa fa-check"></i><b>3.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="3.1.2" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-2----"><i class="fa fa-check"></i><b>3.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html"><i class="fa fa-check"></i><b>3.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="3.2.1" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>3.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="3.2.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>3.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="3.2.3" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-3-------"><i class="fa fa-check"></i><b>3.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>4</b> ACREP</a><ul>
<li class="chapter" data-level="4.1" data-path="observational-study.html"><a href="observational-study.html"><i class="fa fa-check"></i><b>4.1</b> Observational Study</a><ul>
<li class="chapter" data-level="4.1.1" data-path="observational-study.html"><a href="observational-study.html#contents"><i class="fa fa-check"></i><b>4.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html"><i class="fa fa-check"></i><b>4.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="4.2.1" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-yes"><i class="fa fa-check"></i><b>4.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="4.2.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-no"><i class="fa fa-check"></i><b>4.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="4.2.3" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#contents-1"><i class="fa fa-check"></i><b>4.2.3</b> Contents</a></li>
<li class="chapter" data-level="4.2.4" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#conclusion"><i class="fa fa-check"></i><b>4.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html"><i class="fa fa-check"></i><b>4.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="4.3.1" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>4.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="4.3.2" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---biomarker"><i class="fa fa-check"></i><b>4.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="-.html"><a href="-.html"><i class="fa fa-check"></i><b>4.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="4.5" data-path="-clinical-prediction-model-individual-riskoutcome-probability-.html"><a href="-clinical-prediction-model-individual-riskoutcome-probability-.html"><i class="fa fa-check"></i><b>4.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="4.6" data-path="web-r-org.html"><a href="web-r-org.html"><i class="fa fa-check"></i><b>4.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="4.6.1" data-path="web-r-org.html"><a href="web-r-org.html#contents-2"><i class="fa fa-check"></i><b>4.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="prism.html"><a href="prism.html"><i class="fa fa-check"></i><b>5</b> Prism</a><ul>
<li class="chapter" data-level="5.1" data-path="morning.html"><a href="morning.html"><i class="fa fa-check"></i><b>5.1</b> Morning</a><ul>
<li class="chapter" data-level="5.1.1" data-path="morning.html"><a href="morning.html#lim-covariate-model"><i class="fa fa-check"></i><b>5.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="5.1.2" data-path="morning.html"><a href="morning.html#fda---lee"><i class="fa fa-check"></i><b>5.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="5.1.3" data-path="morning.html"><a href="morning.html#pfizer"><i class="fa fa-check"></i><b>5.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html"><i class="fa fa-check"></i><b>5.2</b> PRISM Afternoon</a><ul>
<li class="chapter" data-level="5.2.1" data-path="prism-afternoon.html"><a href="prism-afternoon.html#kim"><i class="fa fa-check"></i><b>5.2.1</b> Kim</a></li>
<li class="chapter" data-level="5.2.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>5.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="5.2.3" data-path="prism-afternoon.html"><a href="prism-afternoon.html#mbdd"><i class="fa fa-check"></i><b>5.2.3</b> MBDD</a></li>
<li class="chapter" data-level="5.2.4" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>5.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="5.2.5" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>5.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><a href="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><i class="fa fa-check"></i><b>6</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="6.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html"><i class="fa fa-check"></i><b>6.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="6.1.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>6.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="6.1.2" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>6.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><i class="fa fa-check"></i><b>6.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="6.2.1" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#considerations-for-drug-development-for-rare-diseases"><i class="fa fa-check"></i><b>6.2.1</b> Considerations for drug development for rare diseases :</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="session-3-lessons-and-learned-rd-for-rare-disease.html"><a href="session-3-lessons-and-learned-rd-for-rare-disease.html"><i class="fa fa-check"></i><b>6.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a></li>
<li class="chapter" data-level="6.4" data-path="session-4-asan-initia-tives-for-rare-disease.html"><a href="session-4-asan-initia-tives-for-rare-disease.html"><i class="fa fa-check"></i><b>6.4</b> Session 4 Asan initia tives for rare disease</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="second-session" class="section level2">
<h2><span class="header-section-number">2.3</span> Second Session</h2>
<ul>
<li>Chair : Yong-Bok Lee(Chonnam National University)</li>
</ul>
<div id="the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers" class="section level3">
<h3><span class="header-section-number">2.3.1</span> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</h3>
<ul>
<li>Speaker : Eileen Dolan (The University of Chicago, USA)</li>
<li>Ototoxicity, CTx Toxicity - hearing loss, peripheral neuropathy</li>
<li>dose-limiting toxicity - platinum, taxanes, vinca, epothilones, bortezomib</li>
<li>numbness, tingling, burning/stabbing pain</li>
<li>partially , can be permanent</li>
<li>Duloxetine - SNRI - CIPN</li>
<li>pharmacogenomic studies - optimal model - testicular cancer -</li>
<li>platinating agents</li>
<li>CIPN - &gt;300mg/m2, dorsal root g. cell apoptosis, affects large neurons, axonal projections</li>
<li>CTCAE of CIPN, patient-reported measures preferred (CIPN EORTC-CPIN20)</li>
<li>PCA analysis</li>
<li>age, smoking</li>
<li>GWAS - CIPN6 -&gt; CAMTA1, RGS, WDR1, MAPK9, COA1, ILR2A</li>
<li>Polygenic architecture</li>
<li>PIPN : ECOG: rs3125923</li>
<li>Stem cells - problems - identifying, priortizing</li>
<li>cell-based PD analysis</li>
<li>iPSC technology in PGx, CRISPR</li>
<li>Neuronal measurements - total outgrowth processes, process length, branches, cell body area</li>
<li>C, P, 5FU, Bortezomib, Vinc, Thalidomide</li>
<li>inhibition of neurite outgrowth</li>
<li>VIN - GWAS 2000 patients</li>
<li>CEP72 - microtubules assembly, TT allele - susceptible -&gt; lower CEP72 mRNA expression</li>
<li>knockdown of CEP72 in iPCSC -&gt; enhancing sensitivity to vincristine</li>
</ul>
<div id="questions---neurite-outgrowth" class="section level4">
<h4><span class="header-section-number">2.3.1.1</span> Questions - neurite outgrowth</h4>
<ul>
<li>Neurons- mature enough?</li>
</ul>
</div>
</div>
<div id="pharmacogenomics-and-epigenomics" class="section level3">
<h3><span class="header-section-number">2.3.2</span> 15:50~16:20 Pharmacogenomics and Epigenomics</h3>
<ul>
<li>Speaker: Matthias Schwab (IKP Stuttgart, Germany)</li>
<li>Prognostic predictors</li>
<li>Genetic make-up</li>
<li>135 FDA-approved drugs with labeled pharmacogenomic information (2015-05-20)</li>
<li>top 30 drugs with pharmacogenetic risk (w/ or w/o high-risk diplotype for gene)</li>
<li>Genomics, proteomics metabolomics, microbiomics</li>
<li>Genome Medicine 2016 (Auffray, Schwab)</li>
<li>NEJM</li>
<li>Cocktail approach - a single dose PK study - old fashion clinical pharmacology approach? -</li>
<li>Metoprolol and Torsemide PK - heretability</li>
<li>Koryza Genet Med 2016 - comprehensive analysis - ESP project (n=6500) and 1000 genomes project</li>
<li>PNAS 2005 Fraga - Epigenomics and DNA methylation</li>
<li>miRNA, methylation, histone modification(acetylation)</li>
<li>CPT 2016, Fisel, Schaeffeler, Schwab - DNA methylation and its impact on disease pathophysioloy and drug therapy</li>
<li>Heatmap - ADME genes - SLC transporters</li>
</ul>
<div id="my-quesion" class="section level4">
<h4><span class="header-section-number">2.3.2.1</span> My Quesion</h4>
<ul>
<li>Can we develop therapeutics which target locus of epigenetic (Decitabine)- Renal cancer cell - treatment of decitabine - demethylating agents (Specificity?)</li>
<li>Epigenomics</li>
</ul>
</div>
</div>
<div id="emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis" class="section level3">
<h3><span class="header-section-number">2.3.3</span> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</h3>
<ul>
<li>Speaker: Young-Jin Chun (Chung-Ang University, KOREA)</li>
<li>P450 (CYP1B1)</li>
<li>Estrogen metabolism : E2-&gt;4-OHE2(endogenous mutagen)</li>
<li>ZYC300 cancer vaccine - CYP1B1 DNA Vaccine</li>
<li>Immunity to CYP1B1 -&gt; Clinical benefit</li>
<li>과발현시 - PCNA increased</li>
<li>TMS - specific human CYP1B1 - DMBA-&gt;PPCNA increased, DMBA+TMS-&gt;PBNA back to normal</li>
<li>CYP1B1 -&gt; EMT (ECADHERIN, ZEB1, Vimentin, twist1 ) FUNCTIONAL STUDY , Can we transmembrane migration - cancer progression</li>
<li>SP1 Transctiption factors - Mithramycin A(binding inhibittor) DMBA에의해 증가한 에스피1등이 mitA를 억제.</li>
<li>이러한 결과들을 통해서 SP1이 암 증식 chip assay</li>
<li>4OHE는 EMT 촉진된다.</li>
<li>억제 - Mithramycin A</li>
<li>촉진 - DMBA, CYP1B1, SP1, 4OHE</li>
<li>Matrigel, migration -&gt; migration, invasion</li>
</ul>
<div id="section" class="section level4">
<h4><span class="header-section-number">2.3.3.1</span> </h4>
<p>1B1에 의해 대사되는 irinotecan - 알수가 없다. Tumor 조직을 갖고 enzyme activity 측정전에. active metabolism 2D6는 steroid</p>
</div>
</div>
<div id="omics-for-precision-medicine-clinical-implementation-in-oncology" class="section level3">
<h3><span class="header-section-number">2.3.4</span> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</h3>
<ul>
<li>Speaker: Kyu-pyo Kim (University of Ulsan College of Medicine, KOREA)</li>
<li>effects are not immediate / severe adverse effects / narrow therapeutic window</li>
<li>UGT1A1 genotypes - different enzyme activities , Irinotecan</li>
<li>Irinotecan -&gt; practical decision making - not reached.</li>
<li>genotype information - strong enough?</li>
<li>neutropenia, diarrhea</li>
<li>mutations are abundant - mutational loading (high- melanoma, lung sq cel carcinoma)</li>
<li>Point mutations, copy # variation -&gt; omics + NGS -&gt; clinical interpretation -&gt; clinical decision making</li>
<li>Ca Cancer J Clin 2016 - 1 month TIME IS IMPORTANT FOR PATIENTS.</li>
<li>Issues : Forces or hurdles - COSTS - volume of patients/turnaround time/Central testing/Quality control</li>
<li>NCI-Match - somatic mutation - Oncomine Comprehensive Assay Gene List - How to report???</li>
<li>KRAS A146 mutation in CRC -&gt; CTX guideline - clinical trial</li>
<li>CPCM - KCSG 11th methodology -</li>
<li>Transition : from research to practice - CLIA (23andMe)</li>
<li>NGS 임상검사실 인증제도 추진중임.</li>
<li>Summary - abundance of information is helpting us</li>
<li>there are many hurdles</li>
<li>multi-disciplinary efforts are needed.</li>
</ul>

</div>
</div>
<!-- </div> -->
            </section>

          </div>
        </div>
      </div>
<a href="first-session.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="translation-and-convergence-for-future-medicine.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-14-2016-KSCPT.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
